Gamma Secretase Inhibitors and Modulators

DBCAT005541Pharmacologic class

Agents that suppress GAMMA-SECRETASE by inhibiting or modulating its activities. Targeted enzymatic activities include its involvement in accumulation of toxic AMYLOID BETA-PEPTIDES (e.g., Aβ42) in ALZHEIMER DISEASE and activation of NOTCH RECEPTOR mediated SIGNAL PATHWAYS... A DrugBank category of 11 drugs. 1 of them is approved.

Drugs: Avagacestat
Begacestat
E-2012
Itanapraced
MK-0752
MRK-003
Nirogacestat
RG-4733
Semagacestat
Tarenflurbil
Varegacestat

What you can answer from here — as of January 08, 2022

11DrugsEach linked to its full drug card

Listed above

7Drug targetsEvery drug–target pair in the class, with bond type

3Marketed productsAcross the regions we cover, with dosage forms and routes

1Route of administrationHow the drugs in this class are given

Which targets do Gamma Secretase Inhibitors and Modulators share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account